Global Measle Vaccine Market Size By Type (Inactivated Vaccine, Attenuated Vaccine), By Application (Hospital, Scientific Research), By Region, And Segment Forecasts, 2023 to 2032

The Global Measle Vaccine Market was valued at USD 2.9 billion in 2023 and is projected to reach USD 4.8 billion by 2031, growing at a CAGR of 6.6% during the forecast period of 2023–2031. The growth of the measle vaccine market is primarily driven by the rising number of measles outbreaks globally, increasing immunization awareness, government-led vaccination campaigns, and support from global health organizations like WHO and UNICEF. With improved healthcare infrastructure in developing nations and ongoing R&D in combination vaccines, the market is poised for stable growth over the next decade.

Drivers:

1. Resurgence of Measles Cases Worldwide:

Despite efforts toward eradication, recent years have witnessed a resurgence in measles outbreaks due to declining immunization rates, prompting renewed focus on vaccination.

2. Global Immunization Programs:

National immunization schedules and initiatives by global organizations have significantly driven demand for routine measles vaccination, especially in low- and middle-income countries.

3. Growing Pediatric Population:

An expanding child population globally requires timely immunization against measles, boosting vaccine demand.

Restraints:

1. Vaccine Hesitancy and Misinformation:

Skepticism and misinformation about vaccine safety continue to challenge market growth, particularly in developed regions.

2. Cold Chain and Distribution Barriers:

Maintaining the cold chain, especially in remote and underdeveloped regions, adds complexity to vaccine distribution.

Opportunity:

1. Advancements in Combination Vaccines (MMR & MMRV):

Rising adoption of combination vaccines that protect against multiple diseases (measles, mumps, rubella, varicella) offers cost-effective and efficient immunization, fostering market expansion.

2. Public-Private Collaborations:

Collaborations between governments, NGOs, and private firms are enabling better outreach, logistics, and vaccine penetration, especially in underserved areas.

Market by System Type Insights:

Based on vaccine type, the Monovalent Measles Vaccine segment accounted for a significant share in 2023 due to its inclusion in many national immunization programs. However, the MMR (Measles-Mumps-Rubella) vaccine segment is projected to grow at the highest CAGR, supported by its broader protective benefits and global preference for combination vaccines.

Market by End-use Insights:

By end-use, the Public Health Agencies segment dominated the market in 2023. These agencies procure large volumes of vaccines for immunization drives. The Hospitals and Clinics segment is also growing steadily, driven by rising private healthcare investments and access to routine immunization services.

Market by Regional Insights:

Asia-Pacific emerged as the largest regional market in 2023, driven by high birth rates, frequent measles outbreaks, and strong government initiatives in countries like India, China, and Indonesia. Africa is expected to witness the fastest growth during the forecast period due to increased international aid and expanding immunization coverage.

Competitive Scenario:

Key players operating in the Global Measle Vaccine Market include:

Merck & Co., Inc.

Serum Institute of India

GlaxoSmithKline plc

Bharat Biotech

Sanofi Pasteur

Zydus Lifesciences

Biovac Institute

These companies are actively investing in vaccine development, global distribution networks, and expansion into emerging markets. Strategic partnerships with government bodies and NGOs are also shaping the competitive landscape.

Scope of Work – Global Measle Vaccine Market

Report Metric Details

Market Size (2023) USD 2.9 Billion

Projected Market Size (2031) USD 4.8 Billion

CAGR (2023–2031) 6.6%

Market Segments Vaccine Type (Monovalent, MMR, MMRV), End-Use (Hospitals, Public Health Agencies)

Growth Drivers Rising measles outbreaks, government immunization campaigns, growing pediatric population

Opportunities Combination vaccine development, public-private immunization partnerships

Key Market Developments:

2023: Serum Institute of India expanded production capacity for its WHO-prequalified measles vaccines to meet growing demand across Africa and Southeast Asia.

2024: GSK announced a new generation of thermostable combination vaccines targeting measles, mumps, and rubella for regions with limited cold chain infrastructure.

2025: Merck & Co. received expanded approval for its MMR vaccine in Latin America following positive post-marketing surveillance data.

FAQs:

1. What is the current market size of the Global Measle Vaccine Market?

The Global Measle Vaccine Market was valued at USD 2.9 billion in 2023.

2. What is the major growth driver of the Global Measle Vaccine Market?

The major growth driver is the resurgence of measles outbreaks and increased government focus on immunization campaigns.

3. Which is the largest region during the forecast period in the Global Measle Vaccine Market?

Asia-Pacific is the largest region due to high birth rates and robust immunization programs.

4. Which segment accounted for the largest market share in the Global Measle Vaccine Market?

The Public Health Agencies segment held the largest market share by end-use in 2023.

5. Who are the key market players in the Global Measle Vaccine Market?

Key players include Merck & Co., Serum Institute of India, GSK, Sanofi Pasteur, and Bharat Biotech.